Trade Association Materials

(2021)

DTWG is providing access to certain public materials from other stakeholders as a convenience.  The inclusion of this material does not necessarily reflect the positions or views of DTWG or its members.

• October 26, 2020 – American Clinical Laboratory Association Comments On VALID Act (HERE)
• August 20, 2020 – AdvaMed Statement on HHS Rescission of Policies on Laboratory Developed Tests During COVID and Beyond (HERE)
• March 5, 2020 – American Clinical Laboratory Association Comments On VALID Act of 2020 (HERE)
• April 2, 2019 – College of American Pathologists Laboratory-Developed Test Oversight FAQs (HERE)
• February 19, 2019 – College of American Pathologists letter on VALID (HERE)
• February 15, 2019 – AdvaMedDx VALID Act Comments (HERE)
• August 20, 2018 – ACLA Comments on DAIA FDA TA (HERE)
• April 7, 2017 – ACLA Comments on DAIA Discussion Draft (HERE)
• April 7, 2017 – College of American Pathologists letter on DAIA (HERE)
• December 13, 2015 – Association for Molecular Pathology Report: Facts FDA Ignored: An analysis of the FDA report, “The Public Health Evidence for FDA Oversight of Laboratory Developed Tests: 20 Case Studies.” (HERE)
• February 2, 2015 – Comments of the Association for Molecular Pathology to FDA (HERE)